The Biotechnology Industry Organization (BIO) and ViS Research are expanding the Pediatric Clinical Research Group, launched in 2013, to include pediatric research sites. BIO and its member companies work with ViS to use its online analytics platform to evaluate global pediatric clinical research infrastructure, identify pediatric patient populations, and empower clinical research collaboration. The aim of the Pediatric Clinical Research Group is to help member companies more efficiently assess the global pediatric clinical research landscape and to engage sites more easily for pediatric clinical studies, according to a BIO press release. The initiative also hopes to enable comprehensive mapping of the pediatric patient population with live feeds of local patient demographics, reduce the site burden from feasibility assessments, and decrease site start-up time.
“Our partnership with ViS Research Institute is helping streamline pediatric clinical research worldwide,” said BIO President and CEO Jim Greenwood in the press release. “ViS Analytics will help drug developers identify pediatric research sites, making it faster and easier to conduct pediatric clinical trials and, ultimately, deliver treatments and cures to children suffering from life threatening and debilitating diseases.”
“Innovative research approaches through analytics are needed to improve success in these most challenging pediatric drug development programs with more timely access for these new drugs in children,” said Dr. Ron Portman, Immediate Past Chair of BIO’s Pediatrics Committee.